10-Q: Ovid Therapeutics Q3 2025: Capital Raise Boosts Runway

Ovid Therapeutics reported a net loss of $12.2 million for Q3 2025, but a recent $75.7 million private placement significantly extends its cash runway.

Summary

• Net loss for the three months ended September 30, 2025, was $12.2 million, an improvement from $14.0 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $27.1 million, compared to $17.2 million for the same period in 2024.
• Total revenue for Q3 2025 was $0.1 million, down from $0.2 million in Q3 2024, while year-to-date revenue significantly increased to $6.5 million from $0.5 million in 2024, primarily due to an amendment to the Marinus License Agreement.
• Research and development (R&D) expenses decreased by $2.0 million in Q3 2025 to $5.9 million, and by $11.9 million for the nine months to $19.0 million, mainly due to the pause of the OV888 (GV101) program and organizational restructuring.
• General and administrative (G&A) expenses increased by $1.2 million in Q3 2025 to $6.8 million, primarily due to business development professional fees. For the nine months, G&A decreased by $3.1 million to $17.7 million due to restructuring and headcount reduction.
• Cash, cash equivalents, and marketable securities totaled $25.6 million as of September 30, 2025.
• A private placement completed on October 6, 2025, generated $75.7 million in net proceeds, which is expected to fund operations for more than 12 months.
• The company announced positive topline Phase 1 trial data for its next-generation GABA-aminotransferase inhibitor, OV329, on October 3, 2025.
• The soticlestat program, previously licensed to Takeda, was discontinued in January 2025 after missing primary endpoints in Phase 3 trials.
• The OV888 (GV101) program is currently paused.
• The company regained compliance with Nasdaq's minimum bid price requirement on September 11, 2025.

Sentiment

Score: 6

Explanation: The company secured significant financing and reported positive early-stage clinical data, which are crucial for a development-stage biopharmaceutical company. However, ongoing net losses, the discontinuation of a key late-stage program (soticlestat), and the pause of another program (OV888) temper the overall sentiment. The capital raise provides a necessary runway but also involves significant potential dilution.

Positives

• Successfully completed a private placement in October 2025, raising $75.7 million in net proceeds, significantly extending the cash runway to over 12 months.
• Announced positive topline Phase 1 trial data for OV329, demonstrating strong inhibitory activity and a potential best-in-category safety profile for GABA-aminotransferase inhibitors.
• Regained compliance with Nasdaq's minimum bid price requirement on September 11, 2025, resolving a previous non-compliance notice.
• Net loss decreased in Q3 2025 to $12.2 million compared to $14.0 million in Q3 2024.
• Total revenue for the nine months ended September 30, 2025, increased significantly to $6.5 million from $0.5 million in the prior year, driven by a $7.0 million payment from the amended Marinus License Agreement.
• Research and development expenses decreased by $2.0 million in Q3 2025 and $11.9 million year-to-date, reflecting cost management and program prioritization.
• Fully recovered $1.8 million from a fraudulent funds transfer in January 2025, which was previously recorded as a loss in Q3 2024.

Negatives

• Continued to incur substantial net losses, with $12.2 million for Q3 2025 and an accumulated deficit of $331.4 million as of September 30, 2025.
• The soticlestat program, which was a significant asset, was discontinued by Takeda in January 2025 after missing primary endpoints in Phase 3 trials, eliminating potential future milestone and royalty payments from this program.
• The OV888 (GV101) program is currently paused, indicating a delay or halt in its development.
• General and administrative expenses increased by $1.2 million in Q3 2025, primarily due to business development professional fees.
• Other income (expense), net, decreased significantly for the nine months ended September 30, 2025, compared to 2024, largely due to a one-time $29.0 million gain in 2024 from the royalty monetization liability adjustment related to soticlestat.

Risks

• Will require additional capital to finance operations, which may not be available on acceptable terms, if at all, potentially forcing delays, limits, or termination of drug development efforts.
• Expects to continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
• Operating history may make it difficult to evaluate business success to date and to assess future viability.
• Business could be adversely affected by economic downturns, changes in inflation and interest rates, changes in trade policy, natural disasters, political crises, geopolitical events, or other macroeconomic conditions.
• Ability to raise capital may be limited by applicable laws and regulations, such as SEC rules for Form S-3 if public float is less than $75.0 million.
• May sell additional equity or debt securities or enter into other arrangements to fund operations, which may result in dilution to stockholders and impose restrictions or limitations on the business.
• Sales of a substantial number of common stock shares in the public market could cause the market price of common stock to drop significantly.
• Is early in drug development efforts; inability to successfully develop, receive regulatory approval for, and commercialize drug candidates, or significant delays, will harm the business.
• Future success is dependent on the successful clinical development, regulatory approval, and commercialization of current and future drug candidates.
• Results of preclinical studies or earlier clinical trials are not necessarily predictive of future results; drug candidates may not have favorable results in planned or future trials or receive regulatory approval.
• Interim topline and preliminary results from clinical trials may change as more patient data becomes available and are subject to audit and verification procedures.
• Preclinical studies and clinical trials are very expensive, time-consuming, and difficult to design and implement, involving uncertain outcomes; substantial delays or failure to demonstrate safety and efficacy may occur.
• If not successful in discovering, developing, and commercializing additional drug candidates, ability to expand business and achieve strategic objectives would be impaired.
• Drug candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial potential, or result in significant negative consequences following any potential marketing approval.
• Even if current or future drug candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community.
• Relationships with customers, physicians, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations.
• Coverage and adequate reimbursement may not be available for current or any future drug candidates, which could make it difficult to sell profitably, if approved.
• If unable to obtain and maintain patent protection for current or any future drug candidates, or if the scope of the patent protection obtained is not sufficiently broad, may not be able to compete effectively.
• May be involved in lawsuits to protect or enforce patents, the patents of licensors, or other intellectual property rights, which could be expensive, time-consuming, and unsuccessful.
• Does not have own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of current and any future drug candidates.
• Intends to rely on third parties to conduct, supervise, and monitor preclinical studies and clinical trials, and unsatisfactory performance by those third parties may harm the business.
• May need to expand organization and may experience difficulties in managing this growth, which could disrupt operations.
• May be subject to numerous and varying privacy and security laws, and failure to comply could result in penalties and reputational damage.
• Previously identified material weaknesses in internal control over financial reporting; future failure to maintain an effective system could adversely affect investor confidence.
• If fails to satisfy all applicable requirements of Nasdaq and it determines to delist common stock, the delisting could adversely affect market liquidity and stock price.

Future Outlook

Management believes existing cash, cash equivalents, marketable securities, and the $75.7 million net proceeds from the recent private placement are sufficient to fund operating and capital expenditure requirements for a period greater than 12 months from the issuance date of the financial statements. The company expects to continue incurring significant expenses and operating losses for at least the next several years as it advances its drug candidates through preclinical and clinical development, builds its portfolio, seeks marketing approvals, and establishes commercial infrastructure. A third drug candidate is expected to begin a clinical trial in the second quarter of 2026.

Management Comments

• Management believes existing cash, cash equivalents and marketable securities, including the proceeds received from the Private Placement, are sufficient to fund its operating and capital expenditure requirements for a period greater than 12 months from the date these unaudited interim condensed consolidated financial statements were issued.
• We expect to continue to incur significant expenses and operating losses for at least the next several years.
• Our team has significant experience with and understanding of epilepsies and other neurological conditions, and we continue to gain insight into the ways the different molecular mechanisms and pathways underlying these disorders impact the symptoms patients experience.
• We have developed a differentiated pipeline of drug candidates containing three novel mechanisms of action (MoAs) to target seizures and believe we are the only company that holds a portfolio of direct activators of potassium-chloride cotransporter 2 (KCC2).

Industry Context

Ovid Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on small molecule medicines for brain conditions with significant unmet need, including epilepsies, psychoses associated with Parkinson's disease, and Lewy body dementia. The company's strategy to develop a differentiated pipeline with novel mechanisms of action, such as KCC2 activators, positions it in a niche but challenging market. The discontinuation of the soticlestat program by Takeda highlights the inherent high risk and uncertainty in late-stage clinical development within the pharmaceutical sector. The recent capital raise is crucial for sustaining operations in a capital-intensive industry, especially given the global economic slowdown, inflation, and high interest rates impacting financing availability for early-stage companies.

Comparison to Industry Standards

• The discontinuation of soticlestat by Takeda after missing Phase 3 endpoints is a common occurrence in drug development, where many promising candidates fail in late-stage trials, similar to other biopharmaceutical companies facing high attrition rates.
• The company's focus on rare CNS disorders, such as Dravet and Lennox-Gastaut syndromes (previously with soticlestat), aligns with a broader industry trend of targeting orphan diseases, which often benefit from expedited regulatory pathways and market exclusivity, though patient recruitment can be challenging.
• The reliance on third-party CROs and CMOs for preclinical and clinical development and manufacturing is a standard practice for smaller biopharmaceutical companies like Ovid, allowing them to conserve capital and leverage specialized expertise, comparable to peers in the development-stage biotech sector.

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• Dr. Jeremy Levin, the company's Chairman and Chief Executive Officer, is currently the Chairman of Gensaic's board of directors, a company in which Ovid Therapeutics has an equity investment and collaboration agreement.
• The CEO participated in the October 2025 Private Placement, purchasing 71 Series B Preferred Shares, 47,333 Series A Warrants, and 35,500 Series B Warrants, pending shareholder approval.
• Takeda, a greater than 5% holder, previously had a collaboration with the company, which included a standstill provision, voting obligations, and transfer restrictions, as per the RLT Agreement.

Stakeholder Impact

• Shareholders face potential dilution from the recent private placement and future equity offerings, but benefit from extended cash runway and continued pipeline development.
• Employees were impacted by organizational restructuring and headcount reduction in June 2024, but the company continues to attract and retain qualified personnel for its development objectives.
• Future patients stand to benefit from the company's ongoing development of small molecule medicines for brain conditions with significant unmet need, with positive early-stage data for OV329.
• Creditors benefit from the improved liquidity position due to the capital raise, reducing immediate financial risk.
• Licensing partners are impacted by program changes, such as the discontinuation of soticlestat (Takeda, Ligand) and the pause of OV888 (Graviton), while new agreements (Immedica) continue to generate revenue.

Next Steps

• Continue ongoing and planned preclinical and clinical development of drug candidates.
• Build a portfolio of drug candidates through development, acquisition, or in-license.
• Initiate preclinical studies and clinical trials for any additional drug candidates that may be pursued in the future.
• Seek marketing approvals for current and future drug candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure to commercialize any drug candidate for which marketing approval may be obtained.
• Develop, maintain, expand, and protect the intellectual property portfolio.
• Implement operational, financial, and management systems.
• Attract, hire, and retain additional administrative, clinical, regulatory, manufacturing, commercial, and scientific personnel.
• Hold a Special Meeting of Stockholders on December 11, 2025, to approve an authorized share increase and the issuance of shares related to the private placement.
• A third drug candidate is expected to begin a clinical trial in the second quarter of 2026.

Key Dates

Recommendation

The recent capital raise significantly improves the company's liquidity and extends its cash runway, which is a critical positive for a development-stage biopharmaceutical company. The positive Phase 1 data for OV329 also offers a promising early-stage asset. However, the discontinuation of the soticlestat program, the pause of OV888, and continued operating losses highlight the high-risk nature of drug development. The substantial potential dilution from the private placement and future capital needs also weigh on the investment profile. Given these mixed signals, a 'hold' recommendation is appropriate, suggesting investors monitor the progress of the pipeline and the effective use of the newly raised capital before making further investment decisions.

Keywords

Biopharmaceutical, Brain Conditions, Neurological Disorders, Epilepsy, Psychoses, Parkinson's Disease, Lewy Body Dementia, Small Molecule Medicines, Clinical Trials, Drug Development, OV329, OV350, KCC2, OV888, GV101, GABA-aminotransferase inhibitor, ROCK2 inhibitors, Private Placement, Capital Raise, Nasdaq Compliance, SEC Filing, 10-Q, Ovid Therapeutics